![Micha Zimmerman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Micha Zimmerman is the founder of CyOptics, Inc. which was founded in 1999.
He held the title of Vice President-Research & Development from 2009 to 2011.
Dr. Zimmerman also worked as a Principal at SCD.
He received a doctorate degree from Princeton University and an undergraduate degree from Technion-Israel Institute of Technology.
| Unternehmen | Position | Ende |
|---|---|---|
SCD
 SCD Miscellaneous Commercial ServicesCommercial Services SCD is an enzyme that catalyzes fatty acid desaturation, which is incorporated into various lipid-related molecules that regulate multiple cellular properties and processes. The private company is based in Madrid, Spain. SCD expression is regulated by a transcription factor known as SREBF1, which has been identified as a risk factor for Parkinson's disease. In preclinical models, SCD inhibition appears to improve neuronal function and reduce toxicity, leading to enhanced neuronal survival. The disruption of membrane-related biological pathways, such as vesicle trafficking, is closely linked to the formation of Lewy body protein/membrane aggregations, a hallmark pathological feature of Parkinson's disease. | Corporate Officer/Principal | - |
CyOptics, Inc.
 CyOptics, Inc. Electronic ComponentsElectronic Technology Designs, develops and markets optical chips & components | Gründer | 18.08.2011 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
SCD
SCD Miscellaneous Commercial ServicesCommercial Services SCD is an enzyme that catalyzes fatty acid desaturation, which is incorporated into various lipid-related molecules that regulate multiple cellular properties and processes. The private company is based in Madrid, Spain. SCD expression is regulated by a transcription factor known as SREBF1, which has been identified as a risk factor for Parkinson's disease. In preclinical models, SCD inhibition appears to improve neuronal function and reduce toxicity, leading to enhanced neuronal survival. The disruption of membrane-related biological pathways, such as vesicle trafficking, is closely linked to the formation of Lewy body protein/membrane aggregations, a hallmark pathological feature of Parkinson's disease. | Commercial Services |
CyOptics, Inc.
CyOptics, Inc. Electronic ComponentsElectronic Technology Designs, develops and markets optical chips & components | Electronic Technology |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Technion-Israel Institute of Technology
 Technion-Israel Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
